Please assess the completion status of the following clinical trial:

Trial Title: Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Key Inclusion Criteria:~* Participant with clinical diagnosis of acne vulgaris on the face as defined by (excluding the nose and middle zone of approximately 2 centimeter \[cm\]):~  1. Investigator's Global Assessment (IGA) score of 3 (Moderate) or 4 (Severe), with the same score on both sides of the face; and~ 2. A minimum of 20 inflammatory lesions (papules and pustules) in total with at least 10 on each side; and~ 3. No more than 2 nodules (greater than or equal to \[\>=\] 1 cm in diameter) on the face; and~ 4. A minimum of 10 atrophic acne scars in total (\>2 mm)~* Participant with a symmetrical number of the following lesions/scars on the whole face:~  1. Inflammatory and non-inflammatory lesions; and~ 2. Atrophic acne scars (minimum of 4 scars per half-face)~* The participant is a female of non-childbearing potential~* If a female of childbearing, potential uses oral contraceptives that are also approve for treating acne vulgaris~* Other protocol defined inclusion criteria could apply~Key Exclusion Criteria:~* Participant with acne conglobata, acne fulminans, secondary acne, nodulocystic acne and acne requiring systemic treatment~* Participant with any acne cyst on the face or with more than 3 excoriated acne lesions~* Participant with known active or chronic allergies or suspected allergy to trifarotene or excipients of the formulation~* Participant with facial dermal conditions (for example, tattoo, skin abrasion, eczema, sunburned skin, scars, nevi, etc.) that may interfere with study assessments in the opinion of the investigator~* Participant with known impaired hepatic or renal functions, based on medical history

- Gender: ALL
- Minimum Age: 17 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- Trifarotene Vehicle Cream (Type: PLACEBO_COMPARATOR): None
- Trifarotene (CD5789) 50 mcg/g Cream (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).